Diagnostic substance and method for the analysis of metabolism processes in the brain

US8911705B2 · kind B2 · utility

Assignee

• Leibniz-Institut fuer Neurobiologie Stiftung des Oeffentlichen Rechts · DE

Inventors

• Iryna Ziabreva · Whickham, GB
• Petra Henrich-Noack · Dublin, IE
• Juergen Goldschmidt · Magdeburg, DE
• Kathrin Baldauf · Magdeburg, DE
• Henning Scheich · Wolmirstedt, DE
• Klaus Reymann · Magdeburg, DE
• Ulrich Schroeder · Braunschweig, DE
• Claudia Pforte · Wettin, DE
• Monika Riek-Burchardt · Kloster Neuendorf, DE

Key dates

• Filing date: Dec 29, 2006
• Grant date: Dec 16, 2014
• Expiry date: Feb 14, 2029

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K51/0478
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to a diagnostic substance, containing at least one complex of lipophilic anions and metal ions, wherein the lipophilic anions are selected from the group comprising: triethylene tetramine dihydrochloride (TETA), ethyl cysteinate dimer (ECD), methoxyisobutylisonitrile (MIBI), HMPAO (d,l-hexamethylpropylene aminoxime), ethylenediamine N,N,N′,N′-tetraacetanilide (EDTAN), dimethyldithiocarbamate (DMC) and diethyldithiocarbamate (DDC) and glycine N,N′-[1,2-ethanediylbis(oxy-2,1-phenylene)]bis [N-(carboxymethyl)-1,1′-bis[2-(octadecyloxy)ethyl]ester (DP-109), and wherein the metal ions are selected from the group comprising thallium isotopes, lead isotopes, cobalt isotopes and manganese isotopes, together with solvents, adjuvants and/or vehicles. The diagnostic substance is used for investigating metabolic processes in the brain and/or central nervous system (CNS).